Lisata Therapeutics (LSTA) Institutional Ownership $2.90 -0.03 (-1.02%) (As of 01:51 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lisata Therapeutics (NASDAQ:LSTA)CurrentInstitutional OwnershipPercentage8.94%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$136.82KNumber ofInstitutional Sellers(last 12 months)0 Get LSTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lisata Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LSTA Institutional Buying and Selling by Quarter Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Lisata Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/9/2024 Dimensional Fund Advisors LP17,336$60K0.0%+48.2%0.209% 4/23/2024 BML Capital Management LLC284,669$888K0.6%+5.5%3.426% 1/30/2024 BML Capital Management LLC269,839$737K0.6%+10.7%3.315% 2/13/2023 BML Capital Management LLC243,839$617K0.6%N/A3.102% (Data available from 1/1/2016 forward) LSTA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LSTA shares? During the previous two years, the following institutional investors and hedge funds held shares of Lisata Therapeutics shares: BML Capital Management LLC ($888K), Dimensional Fund Advisors LP ($60K).Learn more on LSTA's institutional investors. What percentage of Lisata Therapeutics stock is owned by institutional investors? 8.94% of Lisata Therapeutics stock is owned by institutional investors. Learn more on LSTA's institutional investor holdings. Which institutional investors have been buying Lisata Therapeutics stock? The following institutional investors have purchased Lisata Therapeutics stock in the last 24 months: BML Capital Management LLC ($284.67K), and Dimensional Fund Advisors LP ($5.64K). How much institutional buying is happening at Lisata Therapeutics? Institutional investors have bought a total of 290,308 shares in the last 24 months. This purchase volume represents approximately $753.73K in transactions. Related Companies Kentucky First Federal Bancorp Institutional Ownership Eliem Therapeutics Institutional Ownership Cabaletta Bio Institutional Ownership Oramed Pharmaceuticals Institutional Ownership Annovis Bio Institutional Ownership Nuvectis Pharma Institutional Ownership Eupraxia Pharmaceuticals Institutional Ownership Assertio Institutional Ownership Quince Therapeutics Institutional Ownership Invivyd Institutional Ownership This page (NASDAQ:LSTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.